we like the same things.....lol....this is my biggest
RE: BY THE WAY ...
Nice to see you back spanky , hope all is well :-)
lee, eeez, paul.
Yep sod all really has happened, the price is lower now than when I sold out in November. Would be funny if there was some news soon and price went up, eeez would have to reward his lucky charm then. Anways for those of you in the know it's Crawshaw full year results next week so I'm hoping you'll be calling me a jammy sod then.
Moneyweek article on Big Pharma
"At the nadir of the financial crisis in March 2009, I decided it was time to buy some shares. I wasnâ€™t at all convinced that the market had bottomed out. In fact, I expected it to fall further. But I also thought that there were at least a few blue-chip companies who were probably as cheap as they were ever going to get, bar the entire world collapsing into a black hole. And as we were saying it was time to buy blue chips in MoneyWeek magazine, I also thought it was only right I should have some â€˜skin in the gameâ€™ â€“ in case we were wrong, and the world did collapse into a black hole. Looking back, of course, I wish Iâ€™d bought some gloriously spivvy little Aim stock, or a credit-starved car dealership, or a manufacturer at deathâ€™s door. Iâ€™d have made multiples of my original money. But no. I bought perhaps the most boring blue chip in the entire FTSE 100. The good news is, it looks like it might now be paying offâ€¦ Smart deals in the drugs sector I invested in drugs giant GlaxoSmithKline (LSE: GSK) at the bottom of the market in 2009. Since then, the stock is up around 46% (90% if you include dividends). That's fine, but it's no Asos. It's not even as good as a FTSE 100 tracker, which would have doubled your money including dividends over the same period. But I have to say, I really like this company. Itâ€™s the least-stressful stock Iâ€™ve ever owned. It pays a nice steady dividend. It never falls enough to make you panic, and it never rises enough to make you think â€œis it time to sell?â€ However, it looks like life in the Big Pharma sector might be about to get more exciting. This week the industry caught merger-mania. One of our tips in the New Year edition of MoneyWeek was AstraZeneca, on the basis it was bound to get taken over this year. It seems thatâ€™s whatâ€™s happening now, with a rumoured approach by US giant Pfizer. Meanwhile, Glaxo and Swiss peer Novartis did a very sensible-looking asset swap. Glaxo swapped its cancer research units for Novartis' vaccine business. As John Gapper notes in the FT, this is a clever deal. Both companies get to specialise and focus resources on areas they are good at. To paraphrase Novartisâ€™ chief executive, Novartis can get more value out of Glaxoâ€™s cancer labs than Glaxo can, while Glaxo can make Novartisâ€™ vaccines business work harder. If it works, everyoneâ€™s a winner. Consumers get more new drugs, more quickly. Shareholders and managements avoid the indigestion problems that always come with any big merger. And nobody has to shell out ridiculous fees to investment banks to broker the whole thing. Healthcare stocks
Bonjour MR Spank
Good to see your back I hope things have been better for you pal. A brief summary of what you have missed. I will list them in order so you can follow it easier. 1. **** all 2. No that's about it Good luck to you pal. Kind regards Lee
Spanky is back! Now, I can comfortably predict that the sp will be 40p by the end of next week! ;-)
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.